One Breakthrough

Safe & Effective

Countless Applications

Watch the video to learn more about Cytophage

Future Safe

By 2050, the World Health Organizations predicts that 10 million people a year will be killed by antibiotic resistant superbugs. However, with our bacterio-matched phages, we can give governments, health providers, NGOs, and food growers the tools needed to ensure this doesn’t happen.

Our tailor-made bacteriophages are inexpensive, quick to produce, harmless to humans and animals, better for the environment and highly effective against exposed bacteria. Because of our unique, proprietary technology, we can produce targeted bacteria-killing phages in only weeks to months vs years as is the case with all other phage producers. Best of all, they complement and greatly reduce the need for antibiotics.

Joining the Fight
Against COVID-19

What if we could prevent the SARS-CoV-2 virus (that causes COVID-19) from infecting our bodies by removing it before it gets established?

 This is the question driving Cytophage’s cutting-edge research in an entirely new focus for bacteriophage. The company is working on a phage nasal spray that goes directly to the area where SARS-CoV-2 infects the body – the mucosal membranes in the nose and throat. There, the phage promotes the production of antibodies through an adaptive immune response, giving protection from infection.  This also results in antibodies that move throughout the body, allowing for general immunity in addition to site-specific protection. 

Cytophage’s nasal-delivered vaccine will be comprised of bacteriophage genetically engineered to possess the SARS-CoV-2 spike gene/epitopes that will be produced and displayed on the surface of the phage. The spike gene/epitopes will be

genetically fused to a phage that infects Lactobacillus (the good bacteria added to yogurt and milk). This combination of phage and bacterial species treatment option will enable the phage to only replicate within the Lactobacillusbacterial species provided. With replication, the phage numbers increase to meet the demand needed to generate a robust response against a potential infection by SARS-CoV-2. This approach satisfies many idealistic vaccine product demands of low concentration of inoculum (as the phage will replicate within bacterial species provided and not disturb the resident microbiota in the mucosa and gut), stability at room and refrigerated temperatures, a non-invasive inoculation scheme, and lower manufacturing demands as high concentrations are not required.


Bacteriophage therapy has unlimited uses and is effective in eradicating bacterial disease and infection in three key areas.

Food Safety

In food safety, our phages help prevent disease and the spread of disease, without introducing antibiotics into the food chain or the environment.

Animal Health

Cytophage is developing bacteriophages that will reduce and ultimately replace the use of antibiotics for illness prevention and growth enhancement in livestock, starting with poultry.

Human Health

In human health, phages can address a full range of bacterial illnesses and conditions, from treating acne and eczema, alleviating internal bacterial infections such as pneumonia, preventing wound infections and battling outbreaks such as cholera or diphtheria.

Phages can also be used for the decontamination of hospital surfaces and counters, tools and instruments, beds and curtains, and anywhere else bacterial contamination is a concern.

Cytophage in the news

News Release

Cytophage Update on Upcoming Product for Egg Production in Canada

Winnipeg, February 12, 2024 – Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to announced that it has completed research and development of its OvaPhage product…

Read More

News Release

Cytophage Technologies Ltd. Announces First Day of Trading

Winnipeg, MB – February 7, 2024 – Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV:CYTO) (formerly Cuspis Capital III Ltd. (“Cuspis”) (TSXV:CIII.P)) is pleased to announce…

Read More

News Release

Cytophage Technologies Ltd. Completes Reverse Takeover Transaction of Cuspis Capital III Ltd.

TORONTO, CANADA, February 2, 2024 – Cytophage Technologies Ltd. (“Cytophage” or the “Resulting Issuer”) (formerly Cuspis Capital III Ltd. (“Cuspis”)) is pleased to announce the completion…

Read More

What is a

Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.

What is a

Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.

We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.

Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.

Swine Bacteriophage

We’re helping farmers meet the need and the demand for a healthier food chain.

Funded in part by the Canada and Manitoba governments through the Canadian Agricultural Partnership – Ag Action Manitoba Program. Learn more

Contact Us

Learn more about our bacteriophage solutions.

Cytophage Technologies Inc. © 2019